Esophageal Cancer Education
Esophageal cancer treatment has been reshaped by checkpoint inhibitor combinations in first-line therapy, with PD-L1 expression, histology, and HER2 status driving treatment decisions. Knowledge Med sessions help physicians navigate this evolving landscape through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing esophageal cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting first-line therapy based on PD-L1 CPS, histology (SCC vs adenocarcinoma), and HER2 status
- Integrating perioperative chemoimmunotherapy for resectable disease
- Managing second-line options after immunotherapy-chemotherapy progression
- Coordinating multidisciplinary care across surgery, radiation, and systemic therapy
What Sessions Cover
Knowledge Med Esophageal Cancer sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy-chemotherapy in advanced esophageal cancer
- Squamous cell vs adenocarcinoma: treatment algorithm differences
- Perioperative nivolumab and emerging neoadjuvant strategies
- HER2-targeted approaches and biomarker-driven treatment selection
Interactive Esophageal Cancer Sessions
Case Simulations
Work through realistic esophageal cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Esophageal Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Esophageal Cancer Session
Third-party, non-promotional esophageal cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session